233 related articles for article (PubMed ID: 25245603)
1. High-mobility group AT-hook 2: an independent marker of poor prognosis in intrahepatic cholangiocarcinoma.
Lee CT; Wu TT; Lohse CM; Zhang L
Hum Pathol; 2014 Nov; 45(11):2334-40. PubMed ID: 25245603
[TBL] [Abstract][Full Text] [Related]
2. Different expression of glucose transporters in the progression of intrahepatic cholangiocarcinoma.
Kubo Y; Aishima S; Tanaka Y; Shindo K; Mizuuchi Y; Abe K; Shirabe K; Maehara Y; Honda H; Oda Y
Hum Pathol; 2014 Aug; 45(8):1610-7. PubMed ID: 24824030
[TBL] [Abstract][Full Text] [Related]
3. CD24 expression is a prognostic factor in intrahepatic cholangiocarcinoma.
Su MC; Hsu C; Kao HL; Jeng YM
Cancer Lett; 2006 Apr; 235(1):34-9. PubMed ID: 16125303
[TBL] [Abstract][Full Text] [Related]
4. The expression of matrix metalloproteinases in intrahepatic cholangiocarcinoma, hilar (Klatskin tumor), middle and distal extrahepatic cholangiocarcinoma, gallbladder cancer, and ampullary carcinoma: role of matrix metalloproteinases in tumor progression and prognosis.
Kirimlioğlu H; Türkmen I; Başsüllü N; Dirican A; Karadağ N; Kirimlioğlu V
Turk J Gastroenterol; 2009 Mar; 20(1):41-7. PubMed ID: 19330734
[TBL] [Abstract][Full Text] [Related]
5. Tenascin expression at the invasive front is associated with poor prognosis in intrahepatic cholangiocarcinoma.
Aishima S; Taguchi K; Terashi T; Matsuura S; Shimada M; Tsuneyoshi M
Mod Pathol; 2003 Oct; 16(10):1019-27. PubMed ID: 14559985
[TBL] [Abstract][Full Text] [Related]
6. Fascin overexpression is involved in carcinogenesis and prognosis of human intrahepatic cholangiocarcinoma: immunohistochemical and molecular analysis.
Iguchi T; Aishima S; Taketomi A; Nishihara Y; Fujita N; Sanefuji K; Sugimachi K; Yamashita Y; Maehara Y; Tsuneyoshi M
Hum Pathol; 2009 Feb; 40(2):174-80. PubMed ID: 18835624
[TBL] [Abstract][Full Text] [Related]
7. Metallothionein overexpression and its prognostic relevance in intrahepatic cholangiocarcinoma and extrahepatic hilar cholangiocarcinoma (Klatskin tumors).
Schmitz KJ; Lang H; Kaiser G; Wohlschlaeger J; Sotiropoulos GC; Baba HA; Jasani B; Schmid KW
Hum Pathol; 2009 Dec; 40(12):1706-14. PubMed ID: 19683330
[TBL] [Abstract][Full Text] [Related]
8. The utility of keratin 903 as a new prognostic marker in mass-forming-type intrahepatic cholangiocarcinoma.
Aishima S; Asayama Y; Taguchi K; Sugimachi K; Shirabe K; Shimada M; Sugimachi K; Tsuneyoshi M
Mod Pathol; 2002 Nov; 15(11):1181-90. PubMed ID: 12429797
[TBL] [Abstract][Full Text] [Related]
9. Down-regulation of aquaporin-1 in intrahepatic cholangiocarcinoma is related to tumor progression and mucin expression.
Aishima S; Kuroda Y; Nishihara Y; Taguchi K; Iguchi T; Taketomi A; Maehara Y; Tsuneyoshi M
Hum Pathol; 2007 Dec; 38(12):1819-25. PubMed ID: 17854859
[TBL] [Abstract][Full Text] [Related]
10. Cell adhesion molecules P-cadherin and CD24 are markers for carcinoma and dysplasia in the biliary tract.
Riener MO; Vogetseder A; Pestalozzi BC; Clavien PA; Probst-Hensch N; Kristiansen G; Jochum W
Hum Pathol; 2010 Nov; 41(11):1558-65. PubMed ID: 20621328
[TBL] [Abstract][Full Text] [Related]
11. The expressions of HMGA2 and Thy1 in extrahepatic cholangiocarcinoma and their clinicopathological significances.
Liu R; Yang Z; Huang S; Li D; Zou Q; Yuan Y
Surg Oncol; 2019 Jun; 29():41-47. PubMed ID: 31196492
[TBL] [Abstract][Full Text] [Related]
12. Dyskerin expression in human fetal, adult and neoplastic intrahepatic bile ducts: correlations with cholangiocarcinoma aggressiveness.
Vasuri F; Rocchi L; Degiovanni A; Giunchi F; Brandi G; Treré D; Montanaro L; D'Errico-Grigioni A
Histopathology; 2015 Jan; 66(2):244-51. PubMed ID: 25367684
[TBL] [Abstract][Full Text] [Related]
13. Correlation of aPKC-iota and E-cadherin expression with invasion and prognosis of cholangiocarcinoma.
Li Q; Wang JM; Liu C; Xiao BL; Lu JX; Zou SQ
Hepatobiliary Pancreat Dis Int; 2008 Feb; 7(1):70-5. PubMed ID: 18234642
[TBL] [Abstract][Full Text] [Related]
14. α-Fetoprotein-producing gastric carcinoma and combined hepatocellular and cholangiocarcinoma show similar morphology but different histogenesis with respect to SALL4 expression.
Ikeda H; Sato Y; Yoneda N; Harada K; Sasaki M; Kitamura S; Sudo Y; Ooi A; Nakanuma Y
Hum Pathol; 2012 Nov; 43(11):1955-63. PubMed ID: 22516245
[TBL] [Abstract][Full Text] [Related]
15. [Result of p53, ki-67 protein expression in cholangiocarcinoma with in situ hybridization and immunohistochemistry methods].
Wang X; Zhang J; Chen J
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2000 Feb; 22(1):57-60. PubMed ID: 12903495
[TBL] [Abstract][Full Text] [Related]
16. Aberrant expression of alpha-fetoprotein in intrahepatic cholangiocarcinoma: an exceptional occurrence.
Vij K; Wang HL
Int J Surg Pathol; 2008 Apr; 16(2):194-8. PubMed ID: 18417680
[TBL] [Abstract][Full Text] [Related]
17. Overexpression of epithelial-mesenchymal transition-related markers according to cell dedifferentiation: clinical implications as an independent predictor of poor prognosis in cholangiocarcinoma.
Ryu HS; Chung JH; Lee K; Shin E; Jing J; Choe G; Kim H; Xu X; Lee HE; Kim DG; Lee H; Jang JJ
Hum Pathol; 2012 Dec; 43(12):2360-70. PubMed ID: 23084587
[TBL] [Abstract][Full Text] [Related]
18. Clinicopathological correlates of aspartyl (asparaginyl) beta-hydroxylase over-expression in cholangiocarcinoma.
Maeda T; Taguchi K; Aishima S; Shimada M; Hintz D; Larusso N; Gores G; Tsuneyoshi M; Sugimachi K; Wands JR; de la Monte SM
Cancer Detect Prev; 2004; 28(5):313-8. PubMed ID: 15542253
[TBL] [Abstract][Full Text] [Related]
19. Clinicopathological prognostic factors after hepatectomy for patients with mass-forming type intrahepatic cholangiocarcinoma: relevance of the lymphatic invasion index.
Shirabe K; Mano Y; Taketomi A; Soejima Y; Uchiyama H; Aishima S; Kayashima H; Ninomiya M; Maehara Y
Ann Surg Oncol; 2010 Jul; 17(7):1816-22. PubMed ID: 20135355
[TBL] [Abstract][Full Text] [Related]
20. The expression of HSP27 is associated with poor clinical outcome in intrahepatic cholangiocarcinoma.
Romani AA; Crafa P; Desenzani S; Graiani G; Lagrasta C; Sianesi M; Soliani P; Borghetti AF
BMC Cancer; 2007 Dec; 7():232. PubMed ID: 18154639
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
